An update of current treatments for adult acute myeloid leukemia

Blood

Volumn 127, Issue 1, 2016, Pages 53-61

  Dombret, Herve ^a,b   Gardin, Claude ^b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c Department of Hematology ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CD135 ANTIGEN; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DECITABINE; ETOPOSIDE; FLUDARABINE; GANETESPIB; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MIDOSTAURIN; PLACEBO; PURINE DERIVATIVE; QUIZARTINIB; SAPACITABINE; SELINEXOR; SORAFENIB; TIPIFARNIB; TOSEDOSTAT; VOLASERTIB; VOSAROXIN;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CYTOGENETICS; DRUG EFFICACY; EVENT FREE SURVIVAL; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; ADULT; LEUKEMIA, MYELOID, ACUTE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

ADULT; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PROGNOSIS;

EID: 84955498114     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-604520     Document Type: Review

References (92)

1. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-121.
2. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
3. Luskin MR, Lee J-W, Fernandez HF, et al. High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk and FLT3-ITD mutant AML: updated analysis from Eastern Cooperative Oncology Trial E1900 [abstract]. Blood. 2014;124(21). Abstract 373.
4. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009; 361(13):1235-1248.
5. Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118(14): 3832-3841.
6. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878-3885.
7. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia aged 50 to 70 years: Results of the ALFA-9801 Study. J Clin Oncol. 2010;28(5): 808-814.
8. Ohtake S, Miyawaki S, Fujita H, et al. Randomized trial of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 Study. Blood. 2011;117(8):2358-2365.
9. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115(3):453-474.
10. Weick JL, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood. 1996;88(8):2841-2851.
11. Bishop JF, Matthews JP, Young GA, et al. Randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87(5):1710-1717.
12. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-1036.
13. Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol. 2014;32(3):219-228.
14. Buchner T, Schlenk RF, Schaich M, et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm: combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012;30(29): 3604-3610.
15. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogeneous leukemia. Blood. 1989; 73(1):24-30.
16. Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential induction to a « 317 » induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104(8):2467-2474.
17. Buchner T, Berdel WE, Schooch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and post-remission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24(16):2480-2489.
18. Braess J, Spiekermann K, Staib P, et al. Dosedense induction with sequential high-dose cytarabine and mitoxantrone (S-HAM) and pelfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: A pilot study of the AMLCG. Blood. 2009;113(17):3903-3910.
19. Petersdorf SH, Kopecky KJ, Slovak M, et al. A Phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860.
20. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloid leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
21. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012; 30(32):3924-3931.
22. Castaigne S, Pautas C, Terŕe C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
23. Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamicin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation: results of the GOELAMS AML 2006 IR study [abstract]. Blood. 2011;118(21). Abstract 79.
24. Burnett AK, Russell N, Hills RK, et al. A comparison of single-dose gemtuzumab ozogamicin 3 mg/m2 and 6 mg/m2 combined with induction chemotherapy in younger patients with AML: data from the UK NCRI AML17 trial [abstract]. Blood. 2014;124(21). Abstract 2308.
25. Amadori S, Suciu S, Stasi R, et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol. 2013;31(35):4424-4430.
26. Löwenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as post-remission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010;115(13):2586-2591.
27. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-Analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986-996.
28. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: A multicenter, randomized phase III study. J Clin Oncol. 2012;30(20):2441-2448.
29. Russell N, Burnett A, Kjeldsen L, et al. A comparison of daunorubicin/ara-c versus daunorubicin/clofarabine as induction treatment in older patients with AML and high-risk MDS: Long term results of the UK NCRI AML16 trial in 806 patients [abstract]. Haematologica. 2015;100(s1). Abstract 514.
30. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360-3368.
31. Thomas X, de Botton S, Chevret S, et al. Clofarabine-based consolidation improves relapse-free survival of younger adults with non-favorable acute myeloid leukemia (AML) in first remission: results of the randomized ALFA-0702/CLARA study [abstract]. Blood. 2015;126(23). Abstract 218.
32. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012;30(20): 2492-2499.
33. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006;108(1):45-51.
34. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28(4):549-555.
35. Willemze R, Suciu S, Muus P, et al. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). Ann Hematol. 2014;93(6):965-975.
36. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25):3110-3118.
37. Röllig C, Muller-Tidow C, Huttmann A, et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-SORAML trial [abstract]. Blood. 2014; 124(21). Abstract 6.
38. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331(14): 896-903.
39. Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121(1):26-28.
40. Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica. 2014;99(11): 1663-1670.
41. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-Aged adults: benefits for whom? Blood. 2007;109(9): 3658-3666.
42. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-Analysis of prospective clinical trials. JAMA. 2009;301(22):2349-2361.
43. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1909-1918.
44. Gooley TA, Chien JW, Pegam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
45. Luznik L, O'Donnell PV, Fuchs EJ. Posttransplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6): 683-693.
46. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
47. Russell NH, Kjeldsen L, Craddock C, et al. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia. 2015;29(7): 1478-1484.
48. Lioure B, Beńe MC, Pigneux A, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an ageadapted strategy: long-term results of a prospective GOELAMS study. Blood. 2012; 119(12):2943-2948.
49. Cornelissen JJ, Versluis J, Passweg JR, et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia. 2015; 29(5):1041-1050.
50. Passweg JR, Labopin M, Cornelissen J, et al. Conditioning intensity in middle-Aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-An observational analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2015;50(8):1063-1068.
51. Brunet S, Martino R, Sierra J. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). Curr Opin Oncol. 2013;25(2):195-204.
52. Pratcorona M, Brunet S, Nomdedeu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-Allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013; 121(14):2734-2738.
53. Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood. 2014;124(2):273-276.
54. Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23): 3441-3449.
55. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: Which platforms are ready for "prime time"? Blood. 2014; 124(23):3345-3355.
56. Kayser S, Walter RB, Stock W, Schlenk RF. Minimal residual disease in acute myeloid leukemia-current status and future perspectives. Curr Hematol Malig Rep. 2015;10(2):132-144.
57. Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33(11):1258-1264.
58. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213-2223.
59. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10): 1813-1821.
60. Boissel N, Renneville A, Leguay T, et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: A French Acute Myeloid Leukemia Intergroup trial. Haematologica. 2015;100(6): 780-785.
61. Paschka P, Schlenk RF, Weber D, et al. Dasatinib (DAS) in combination with chemotherapy and as maintenance in core-binding factor (CBF) acute myeloid leukemia (AML): A phase Ib/IIa study of the German-Austrian AML Study Group (AMLSG) [abstract]. Haematologica. 2015;100(s1). Abstract 515.
62. Marcucci G, Geyer S, Zhao W, et al. Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (Alliance) [abstract]. Blood. 2014; 124(21). Abstract 8.
63. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12): 3294-3301.
64. Knapper S, Hills RK, Cavenagh JD, et al. A randomised comparison of the sequential addition of the FLT3 inhibitor lestaurtinib (CEP701) to standard first line chemotherapy for FLT3- mutated acute myeloid leukemia: The UK experience [abstract]. Blood. 2014;124(21). Abstract 3736.
65. Chen YB, Shuli L, Andrew LA, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for patients with FLT3-ITD AML [abstract]. Blood. 2014;124(21). Abstract 671.
66. Daver N, Cortes J, Ravandi F, et al. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015;125(21): 3236-3245.
67. Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood. 2010;115(5): 948-956.
68. Schlenk RF, Döhner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG trial AML HD98B. Haematologica. 2009;94(1):54-60.
69. Schlenk RF, Döhner K, Krauter J, et al. All-trans retinoic acid improves outcome in younger patients with nucleophosmin-1 mutated acute myeloid leukemia. Results of the AMLSG 07-04 randomized treatment trial [abstract]. Blood. 2011;118(21). Abstract 80.
70. El Hajj H, Dassouki Z, Berthier C, et al. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood. 2015;125(22):3447-3454.
71. Martelli MP, Gionfriddo I, Mezzasoma F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125(22):3455-3465.
72. Jaglal MV, Duong VH, Bello CM, et al. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014;38(4):443-446.
73. Stone RM, Mazzola E, Neuberg D, et al. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015;33(11):1252-1257.
74. Genovese G, K ahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
75. Jaiswal S, Fontanillas P, Flannick J, et al. Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-2498.
76. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- And microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596-604.
77. Gardin C, Chevret S, Pautas C, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol. 2013;31(3):321-327.
78. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydoxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-1124.
79. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
80. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with .30% blasts. Blood. 2015;126(3):291-299.
81. Burnett AK, Russell NH, Culligan D, et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol. 2012;158(4):519-522.
82. Burnett AK, Hills RK, Hunter A, et al. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia. 2011;25(7):1122-1127.
83. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to lowdose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-Awinner comparison. Leukemia. 2013;27(1): 75-81.
84. Dennis M, Russell N, Hills RK, et al. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015;125(19): 2923-2932.
85. Burnett AK, Russell N, Hills RK, et al. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29(6):1312-1319.
86. Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older not improve survival. Blood. 2013;122(8): 1384-1394.
87. Döhner H, Lubbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124(9): 1426-1433.
88. Naval D, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) [abstract]. Blood. 2014;124(21). Abstract 385.
89. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-1978.
90. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31(10):1293-1301.
91. Ravandi F, Ritchie E, Sayar H, et al. Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: results of a phase 3 double-blind randomized controlled multinational study (VALOR) [abstract]. Blood. 2014;124(21). Abstract LBA 6.
92. O'Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw. 2012;10(8):984-1021.